The Board of Directors, at its meeting held today, has approved the transfer of the Company's Nebulizer brands/IP portfolio to Glenmark Healthcare Limited ( GHL ), a wholly owned subsidiary of the Company.
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals' Board has approved transferring its Nebulizer brands and IP portfolio to Glenmark Healthcare Limited (GHL), a wholly owned subsidiary. The Nebulizer business generated Rs. 71.6 Cr revenue in the nine months ended December 2025, representing about 1.3% of Glenmark's standalone revenue. The transfer will be at a cash consideration of Rs. 223 Cr based on an independent valuer's report. The deal is expected to complete by June 30, 2026. GHL is setting up a dedicated Nebulizers manufacturing facility. The transaction is a related party transaction conducted at arm's length, with no change in Glenmark's shareholding pattern.
This intra-group restructuring is relatively small (1.3% of revenue) and should have minimal direct impact on Glenmark's stock. The transfer aims to give the high-growth Nebulizer business sharper strategic focus under a dedicated subsidiary, which could benefit long-term value creation.